Patient Leaflet Updated 17-Sep-2025 | AstraZeneca UK Limited
Nolvadex
Nolvadex® and Nolvadex® D
tamoxifen
Nolvadex and Nolvadex D will be referred to as Nolvadex throughout this leaflet.
1. What Nolvadex is and what it is used for
2. What you need to know before you take Nolvadex
3. How to take Nolvadex
4. Possible side effects
5. How to store Nolvadex
6. Contents of the pack and other information
The name of your medicine is Nolvadex. Nolvadex contains a medicine called tamoxifen, which belongs to a group of medicines called ‘anti-oestrogens’.
If you want to know more about how to decide whether tamoxifen is right for you, there is more information for patients on the National Institute for Health and Care Excellence website. Ask your doctor to talk to you about the information which is available for patients.
Oestrogen is a natural substance in your body known as a ‘sex hormone’. Some breast cancers need oestrogen to grow and Nolvadex works by blocking the effects of oestrogen.
Do not take Nolvadex if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Nolvadex.
Talk to your doctor or pharmacist before taking Nolvadex.
In delayed breast reconstruction operation (weeks to years after the primary breast operation when your own tissue is moved to shape a new breast), Nolvadex may increase the risk of the formation of blood clots in the small vessels of the tissue flap which may lead to complications.
Nolvadex therapy may be used to reduce the risk of breast cancer and it can be associated with serious side effects such as blood clots in the veins of your leg (deep vein thrombosis), blood clots in your lungs (pulmonary embolus) and uterine cancer, all of which can be fatal. Other less serious side effects such as hot flushes, vaginal discharge, menstrual irregularities and pelvis pain may also occur.
Whether the benefits of treatment outweigh the risks depends on your age, health history, your level of breast cancer risk and on your personal judgement. Nolvadex therapy to reduce the risk of breast cancer may not be appropriate for all women at increased risk. All assessments with your healthcare professional of the potential benefits and risks prior to starting therapy are essential. You should understand that Nolvadex reduces, but does not eliminate the risk of breast cancer.
If you have or have had heart problems or an irregular heartbeat (arrhythmia), you may be at a higher risk of changes in your heart’s electrical activity (known as QT prolongation) when using tamoxifen. QT prolongation can be seen on a heart test called an electrocardiogram (ECG) and may increase the risk of serious heart rhythm problems. If you are at an increased risk, your doctor should check your blood for important blood salts and minerals (electrolytes) and check your heart activity with an ECG before and during treatment with Nolvadex.
If you have a history of hereditary angioedema as Nolvadex may cause or worsen symptoms of hereditary angioedema. If you experience symptoms such as swelling of the face, lips, tongue and/or throat with difficulty in swallowing or breathing, contact a doctor immediately.
Serious skin reactions
Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported in association with Nolvadex treatment. Stop using Nolvadex and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.
This medicine is not for use in children.
If you are to undergo planned surgery, you should tell your doctor or pharmacist as they may wish to consider stopping your treatment for a short period.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is because Nolvadex can affect the way some other medicines work and some medicines can have an effect on Nolvadex.
In particular, tell your doctor or pharmacist if you are taking any other medicines:
Women who can become pregnant should use adequate non-hormonal contraception (e.g., barrier contraception) during treatment with Nolvadex and for an additional nine months after stopping treatment.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Breast-feeding
Talk to your doctor before taking Nolvadex if you are breast-feeding.
Nolvadex is not likely to affect your ability to drive or use any tools or machines. However, tiredness has been reported with the use of Nolvadex and caution should be observed when driving or operating machinery while such symptoms persist.
Always take Nolvadex exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose for breast cancer is 20 mg daily.
The dose for infertility depends on your periods (menstrual cycle).
The recommended dose for reducing the risk of breast cancer is 20 mg daily for 5 years. Your healthcare professional will calculate your risk of breast cancer occurring using information about you, your medical history and any family history of breast cancer.
If you take more Nolvadex than you should, talk to a doctor or pharmacist straight away.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
The active substance is tamoxifen.
Each Nolvadex 10 mg tablet contains Tamoxifen Citrate Ph. Eur. 15.2 mg equivalent to 10 mg tamoxifen.
Each Nolvadex D 20 mg tablet contains Tamoxifen Citrate Ph. Eur. 30.4 mg equivalent to 20 mg Tamoxifen.
The other ingredients are croscarmellose sodium, gelatin, lactose, macrogol, magnesium stearate, maize starch, methylhydroxypropylcellulose and titanium dioxide.
Nolvadex 10 mg Tablets are white to off-white, round, biconvex, film-coated tablets, with markings on one face and plain on the reverse. They come in packs (blister strips or bottles) of 30 or 250 tablets.
Nolvadex D 20 mg tablets are octagonal, white film-coated tablets. They are marked Nolvadex D on one side. They come in packs of 30 or 250 tablets.
Not all pack sizes may be marketed.
The Marketing Authorisations for Nolvadex and Nolvadex D are held by
Nolvadex and Nolvadex D are manufactured by
To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge:
0800 198 5000 (UK only)
Please be ready to give the following information:
Product name Reference number
Nolvadex 17901/0033
Nolvadex D 17901/0034
This is a service provided by the Royal National Institute of Blind People.
This leaflet was last revised in August 2025.
© AstraZeneca 2025
Nolvadex is a trade mark of the AstraZeneca group of companies.
ONC 25 0044
2 Pancras Square, 8th Floor, London, N1C 4AG, UK
+44 (0)1582 838 000
www.myazmed.co.uk
+44 (0)1582 836 000
0800 783 0033
https://medicalinformation.astrazeneca.co.uk/